Conavi Medical Successfully Closes $20 Million Offering
Conavi Medical Corp. (TSXV: CNVI; OTC: CNVIF) is thrilled to share the successful closing of its upsized equity public offering, generating an impressive $20 million in gross proceeds. This milestone marks a critical step forward in the company's journey to enhance its innovative imaging solutions.
Use of Proceeds for Future Development
The funds raised during the Offering will significantly enhance the company's capability in advancing its Novasight 3.0 technology. This state-of-the-art imaging technology aims to streamline common minimally invasive cardiovascular procedures. The primary goal is to submit a 510(k) clearance application to the appropriate regulatory authorities, signaling our commitment to innovation and patient care.
Commitment to Innovation
With the net proceeds, Conavi Medical plans to push forward with the development and pre-clinical testing phases of the Novasight 3.0 technology. This strategic investment aims to ensure that the company remains at the forefront of imaging technologies that revolutionize how cardiovascular procedures are performed.
Details on the Offering
Bloom Burton Securities Inc. facilitated the Offering, acting as the sole and exclusive agent. Investors had the opportunity to purchase a combination of common shares priced at $0.40 each or pre-funded common share purchase warrants at $0.39999. In total, 50 million securities were acquired, including 32.5 million common shares and approximately 17.5 million pre-funded warrants, securing the necessary capital for future endeavors.
Structure of the Securities
Each pre-funded warrant provides the holder the right to acquire one common share at an exceedingly nominal price. This flexibility allows investors additional options while promoting active participation in the company's growth.
Compliance and Regulatory Details
Conavi Medical adheres to stringent regulatory requirements. The securities associated with this Offering were registered via a short-form prospectus and were structured for compliance with U.S. securities laws. Despite the complexities, the company ensured that all regulations and compliance measures were met efficiently, demonstrating its commitment to transparency.
Insider Participation
Notably, insiders of Conavi Medical, including CPOINT Capital Corp. and Juno Pharmaceuticals LP, contributed significantly to the Offering. Their participation underscores a strong belief in the company’s future potential and aligns their interests with that of other investors.
About Conavi Medical
Conavi Medical stands out in the medical device field, particularly with its Novasight Hybrid™ System. This innovative system merges intravascular ultrasound (IVUS) and optical coherence tomography (OCT) for a more comprehensive view of coronary arteries during procedures. The company has received essential regulatory approvals in various regions, including the United States and Canada, amplifying its market readiness.
Future Prospects
As Conavi Medical progresses, the focus remains on expanding its product offerings and improving patient outcomes through its imaging technologies. With regulatory approvals already achieved, the company is well-positioned to implement its solutions across multiple healthcare markets.
Frequently Asked Questions
What did Conavi Medical announce recently?
Conavi Medical announced the successful closing of a $20 million equity offering to fund its Novasight 3.0 technology development.
How will Conavi Medical use the funds raised?
The funds will be utilized to advance the Novasight 3.0 technology, covering development and pre-clinical testing phases.
Who acted as the agent for the Offering?
Bloom Burton Securities Inc. served as the sole and exclusive agent for the Offering.
What innovative system does Conavi Medical offer?
Conavi Medical's Novasight Hybrid™ System uniquely combines IVUS and OCT for enhanced imaging during cardiovascular procedures.
What are the next steps for Conavi Medical?
The company intends to submit a 510(k) clearance application for its technology to the U.S. FDA while continuing to develop its offerings.
